Short Interest in Heartflow, Inc. (NASDAQ:HTFL) Expands By 42.4%

Heartflow, Inc. (NASDAQ:HTFL) was the target of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 4,951,283 shares, a growth of 42.4% from the January 15th total of 3,476,809 shares. Based on an average trading volume of 843,019 shares, the days-to-cover ratio is currently 5.9 days. Currently, 5.8% of the company’s stock are sold short. Currently, 5.8% of the company’s stock are sold short. Based on an average trading volume of 843,019 shares, the days-to-cover ratio is currently 5.9 days.

Insider Buying and Selling

In other news, CEO John C.M. Farquhar sold 22,562 shares of Heartflow stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total value of $619,552.52. Following the completion of the transaction, the chief executive officer owned 591,656 shares in the company, valued at approximately $16,246,873.76. This trade represents a 3.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Julie A. Cullivan sold 8,000 shares of Heartflow stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $27.32, for a total transaction of $218,560.00. Following the completion of the transaction, the director owned 36,413 shares of the company’s stock, valued at $994,803.16. This represents a 18.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,030,562 shares of company stock valued at $56,938,113 in the last three months.

Hedge Funds Weigh In On Heartflow

A number of institutional investors have recently modified their holdings of the business. Baillie Gifford & Co. acquired a new stake in Heartflow during the 3rd quarter worth $101,182,000. New York State Common Retirement Fund acquired a new position in Heartflow in the third quarter valued at $4,015,000. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Heartflow in the third quarter valued at about $4,418,000. Board of Trustees of The Leland Stanford Junior University acquired a new stake in shares of Heartflow during the third quarter worth about $10,510,000. Finally, Lisanti Capital Growth LLC purchased a new position in shares of Heartflow during the third quarter worth about $982,000.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HTFL. Stifel Nicolaus boosted their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wells Fargo & Company started coverage on Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price target for the company. JPMorgan Chase & Co. increased their price objective on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Finally, Canaccord Genuity Group upped their price target on Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

Heartflow Stock Down 8.1%

NASDAQ:HTFL opened at $20.66 on Friday. The stock has a market cap of $1.76 billion and a P/E ratio of -11.41. Heartflow has a 52-week low of $20.13 and a 52-week high of $41.22. The stock’s 50 day moving average price is $29.97.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.